Seattle Genetics is a well- known Biotechnology Company that has achieved a lot for individuals who have cancer. The institution is said to be on the brink of expansion. Not long ago, the organization, based in America increased in public stock to more than five million. Clay Siegall, the chief executive officer of the biotechnology company, says that the massive capital was raised successful due to the overwhelming support and interest from the investors. The institution is expected to expand its services and products too.
Seattle Genetics was founded by Clay Siegall and several other partners in the year 1998. Although the biotechnology company has not yet been profitable in its operations, reports say that it is doing very well. Under the leadership of their chairman and chief executive officer, Clay Siegall, the biotechnology company has already produced a cancer drug, known as Adcetris.
Adcetris has been sold in the market in the recent past, and it is doing very well. The cancer drug has been improved several times, and its last improvement was a great success. Since then, the drug has helped to cure over fifteen thousand individuals suffering from different types of cancers. The drug is also accepted in more than sixty nations of the world, and this is a sign that it is very effective in its treatments.
Clay Siegall is a cancer treatment specialist, and he is the guiding force in the biotechnology company. As the chief executive officer and chairman of the board of directors, Clay Siegall has been responsible for the capital raising activities in the enterprise. He is also in charge of the day to day operations in the company, and he has brought many positive changes in the industry.
Before starting the biotechnology company, Clay Siegall had worked in several organizations, and this gave him the expertise and skills needed to launch the institution. Clay has a particular focus on cancer therapies and treatments, and this is one of the reasons he has done so well. As a scientist, Clay has done his best to ensure that the healthcare industry develops the best practices and antibody therapies.